bullish
Legend Biotech (LEGN.US) Offer Update - Is the Deal Really Dead?
484 Views15 Oct 2024 08:55
Given the geopolitical risks, this acquisition is worth considering for both Legend Bio and Genscript. However, the main obstacles are disagreement over price and personnel arrangement for Legend Bio.
What is covered in the Full Insight:
- Introduction - Acquisition Update
- Current Status of the Deal
- Neutral View on Recent Developments
- Obstacles Facing the Acquisition
- Conclusion and Investor Advice
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- Pre-IPO Hangzhou Jiuyuan Gene Engineering (PHIP Updates) - The Future Prospects Are Not Optimistic19 Nov 2024
- Legend Biotech (LEGN.US) Offer Update - Will Deconsolidation Increase the Chances of a Merger ?13 Nov 2024
- Legend Biotech (LEGN.US) Offer Update - The Takeover Negotiations Could Reach an Impasse?03 Sep 2024
- Legend Biotech (LEGN.US) Offer Update - Some New Information About the Takeover Worth the Attention01 Aug 2024
- Legend Biotech (LEGN US) - A Takeover Offer?15 Jul 2024
x